NewsBenzingaEvaxion报告：在晚期黑色素瘤EVX-01单药治疗2期试验中，所有患者在三年内均维持临床应答且无肿瘤进展，89%的疫苗新抗原触发了T细胞反应 Evaxion报告：在晚期黑色素瘤EVX-01单药治疗2期试验中，所有患者在三年内均维持临床应答且无肿瘤进展，89%的疫苗新抗原触发了T细胞反应 Benzinga 2026.10.23 06:10 (GMT+0) Open on Benzinga Other news Meta, Nvidia Lead Tech Sell-Off as AI Spending Fears Rattle Wall Street, But Gene Munster Sides With Musk, Zuckerberg and Huang: ‘We’re Still Early' Western Digital (WDC) Stock Is Trending After Hours: Here’s What You Need to Know ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR Why We're Still Riding With Uber First Hawaiian Likely To Report Higher Q3 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Mohawk Industries Continues Its Strong Growth In A Mixed Market (NYSE:MHK)
Meta, Nvidia Lead Tech Sell-Off as AI Spending Fears Rattle Wall Street, But Gene Munster Sides With Musk, Zuckerberg and Huang: ‘We’re Still Early'
ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR
First Hawaiian Likely To Report Higher Q3 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
